Last updated: April 2026
For expert clinical use only. DoseCurve is intended for use by qualified healthcare professionals as an educational reference tool. It is not intended for use by patients or the general public for self-medication decisions.
DoseCurve is provided for informational and educational purposes only. It is not a medical device, does not provide medical advice, and must not be used as a substitute for professional clinical judgement.
All medication effect profiles displayed on this site are approximations based on published pharmacological research. They represent typical subjective effect curves derived from population-level study data, not individual patient responses.
The creator of DoseCurve accepts no liability for any clinical decisions made using this tool. Specifically:
DoseCurve is designed for:
DoseCurve runs entirely in your browser. No patient data is collected, transmitted, or stored. No analytics or tracking are used. No cookies are set.
Medication effect curves are modelled using Gaussian sum functions fitted to published pharmacodynamic data from laboratory school studies, simulated workplace environment trials, and systematic reviews. Modified-release formulations with multiple internal components (e.g., IR coating + MR beads) use a receptor occupancy union model to combine component curves realistically.
The combining algorithm for same-target drugs uses:
combined(t) = 1 − ∏i(1 − Ei(t))
where Ei(t) is the dose-scaled individual effect at time t. This naturally produces diminishing returns consistent with receptor saturation kinetics.
Brams M, Moon E, Pucci M, Lopez FA. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. Current Medical Research and Opinion 2010;26(8):1809-1825. doi:10.1185/03007995.2010.496015
Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the COMACS Study). Pediatrics 2004;113(3):e206-e216. doi:10.1542/peds.113.3.e206
Sonuga-Barke EJS, Van Lier P, Swanson JM, Coghill D, Wigal S, Vandenberghe M, Hatch S. Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. European Child and Adolescent Psychiatry 2008;17:245-254. doi:10.1007/s00787-007-0667-3
Wigal SB, Kollins SH, Childress AC, Squires L. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child and Adolescent Psychiatry and Mental Health 2009;3:17. doi:10.1186/1753-2000-3-17
Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behavioural and Brain Functions 2010;6:34. doi:10.1186/1744-9081-6-34
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry 2018;5(9):727-738. doi:10.1016/S2215-0366(18)30269-4
Wigal SB, Wigal T, Childress A, Donnelly GAE, Reiz JL. The time course of effect of multilayer-release methylphenidate hydrochloride capsules: a randomized, double-blind study of adults with ADHD in a simulated adult workplace environment. Journal of Attention Disorders 2020;24(3):373-383. doi:10.1177/1087054716672335
Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. Journal of Attention Disorders 2006;10(1):92-111. doi:10.1177/1087054705286049
Dopfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerber-von Muller G, Gunter M, Hassler F, Ose C, Rothenberger A, Schmeck K, Sinzig J, Stadler C, Uebel H, Lehmkuhl G. An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety. European Child and Adolescent Psychiatry 2011;20(Suppl 2):S243-S255. doi:10.1007/s00787-011-0202-4
Dopfner M, Ose C, Fischer R, Ammer R, Scherag A. An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality-of-life outcomes. European Child and Adolescent Psychiatry 2011;20(Suppl 2):S267-S277. doi:10.1007/s00787-011-0205-1
Anderson VR, Keating GM. Methylphenidate controlled-delivery capsules (Equasym XL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder. Paediatric Drugs 2006;8(5):319-333. doi:10.2165/00148581-200608050-00005
Equasym XL Summary of Product Characteristics (SmPC). Electronic Medicines Compendium (EMC). Available at: https://www.medicines.org.uk/emc/product/3887/smpc
Dopfner M, Ose C, Fischer R, Ammer R, Scherag A. Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting. Journal of Child and Adolescent Psychopharmacology 2011;21(5):445-454. doi:10.1089/cap.2010.0082
Huss M, Ginsberg Y, Tvedten T, Arngrim T, Philipsen A, Carter K, Chen CW, Kumar V. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Advances in Therapy 2014;31:44-65. doi:10.1007/s12325-013-0085-5
Medikinet XL Summary of Product Characteristics (SmPC). Electronic Medicines Compendium (EMC). Available at: https://www.medicines.org.uk/emc/product/313/smpc
Stein MA, Sikirica V, Englebienne J. Clinical use of a modified release methylphenidate in the treatment of childhood attention deficit hyperactivity disorder. Expert Opinion on Pharmacotherapy 2012;13(15):2205-2213. doi:10.1517/14656566.2012.726616
Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997;100(4):662-666. doi:10.1542/peds.100.4.662
Castells X, Blanco-Silvente L, Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews 2018;8:CD007813. doi:10.1002/14651858.CD007813.pub3
Huss M, Dirks B, Groom MJ, Arning L, Mowinckel P. Effectiveness and safety of dexamphetamine sulfate (Attentin) in the routine treatment of children and adolescents with ADHD: results from a 12-month non-interventional study. Frontiers in Psychiatry 2021;12:643126. doi:10.3389/fpsyt.2021.643126
Catala-Lopez F, Hutton B, Nunez-Beltran A, Page MJ, Ridao M, Macias Saint-Gerons D, Catala MA, Tabares-Seisdedos R, Moher D. Relationship between treatment duration and efficacy of pharmacological treatment for ADHD: a meta-analysis and meta-regression of 87 randomized controlled clinical trials. Journal of Attention Disorders 2022;26(2):234-242. doi:10.1177/1087054720903372
Kortekaas-Rijlaarsdam AF, Luman M, Sonuga-Barke E, Oosterlaan J. Continued benefits of methylphenidate in ADHD after 2 years in clinical practice: a randomized placebo-controlled discontinuation study. American Journal of Psychiatry 2019;176(9):754-762. doi:10.1176/appi.ajp.2019.18111296
Cappelletti S, Piacentino D, Sani G, Aromatario M. Caffeine: cognitive and physical performance enhancer or psychoactive drug? Current Neuropharmacology 2015;13(1):71-88. doi:10.2174/1570159X13666141210215655
Nehlig A. Is caffeine a cognitive enhancer? Journal of Alzheimer's Disease 2010;20(S1):S85-S94. doi:10.3233/JAD-2010-091315
Quetiapine (Seroquel) Summary of Product Characteristics (SmPC). Electronic Medicines Compendium (EMC). Available at: https://www.medicines.org.uk/emc/product/8814/smpc
Cohrs S, Rodenbeck A, Guan Z, Pohlmann K, Jordan W, Meier A, Ruther E. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology 2004;174(3):421-429. doi:10.1007/s00213-003-1759-5
Zopiclone Summary of Product Characteristics (SmPC). Electronic Medicines Compendium (EMC). Available at: https://www.medicines.org.uk/emc/product/5765/smpc
Noble S, Langtry HD, Lamb HM. Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998;55(2):277-302. doi:10.2165/00003495-199855020-00015
Propranolol Summary of Product Characteristics (SmPC). Electronic Medicines Compendium (EMC). Available at: https://www.medicines.org.uk/emc/product/5765/smpc
Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A. Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. Journal of Psychopharmacology 2016;30(2):128-139. doi:10.1177/0269881115612236
Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. Journal of Clinical Endocrinology and Metabolism 2001;86(10):4727-4730. doi:10.1210/jcem.86.10.7901
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One 2013;8(5):e63773. doi:10.1371/journal.pone.0063773
Diazepam Summary of Product Characteristics (SmPC). Electronic Medicines Compendium (EMC). Available at: https://www.medicines.org.uk/emc/product/4284/smpc
Greenblatt DJ, Shader RI, Divoll M, Harmatz JS. Benzodiazepines: a summary of pharmacokinetic properties. British Journal of Clinical Pharmacology 1981;11(S1):11S-16S. doi:10.1111/j.1365-2125.1981.tb01833.x
Lorazepam Summary of Product Characteristics (SmPC). Electronic Medicines Compendium (EMC). Available at: https://www.medicines.org.uk/emc/product/4942/smpc
Greenblatt DJ, Schader RI, Franke K, MacLaughlin DS, Harmatz JS, Allen MD. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. Journal of Pharmaceutical Sciences 1979;68(1):57-63. doi:10.1002/jps.2600680119
Wigal SB. Laboratory school protocol mini-review: use of direct observational and objective measures to assess ADHD treatment response across the lifespan. Frontiers in Psychology 2019;10:1796. doi:10.3389/fpsyg.2019.01796
Coghill DR, Banaschewski T, Lecendreux M, Zuddas A, Dittmann RW, Otero IH, Civil R, Bloomfield R, Squires LA. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. BMC Psychiatry 2013;13:237. doi:10.1186/1471-244X-13-237
Cortese S, Coghill D. Twenty years of research on ADHD pharmacotherapy: where are we in 2023? Expert Opinion on Pharmacotherapy 2023;24(2):167-177. doi:10.1080/14656566.2023.2169604